A Cost-Effectiveness Analysis of Docetaxel in the Second-Line Treatment of Non-Small Cell Lung Cancer

被引：0
|
作者：
Jeremy Holmes
David Dunlop
Lindsay Hemmett
Peter Sharplin
Uday Bose
机构：
[1] PMSI Healthcare,
[2] Glasgow Royal Infirmary,undefined
[3] Aventis Pharma,undefined
[4] PMSI Healthcare,undefined
[5] White Lion House,undefined
来源：
PharmacoEconomics | 2004年 / 22卷
关键词：
Docetaxel; Well Supportive Care; Administration Cost; Nurse Time; Docetaxel Treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: Whilst lung cancer is the most common form of cancer in England and Wales (annual incidence rate of 50 per 100 000) it does not always receive the policy attention accorded to other types of cancer, such as breast and colorectal. Nevertheless, the burden of lung cancer is significant and the UK NHS Plan for cancer has set out the government’s commitment to improving all cancer services. The question faced by the NHS is which interventions are most cost effective in implementing this plan.
引用
收藏
页码：581 / 589
页数：8
相关论文
共 50 条
  • [1] A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer
    Holmes, J
    Dunlop, D
    Hemmett, L
    Sharplin, P
    Bose, U
    [J]. PHARMACOECONOMICS, 2004, 22 (09) : 581 - 589
  • [2] Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China
    Shi, Yafei
    Chen, Wei
    Zhang, Yujun
    Bo, Mingming
    Li, Chunyu
    Zhang, Mingyu
    Li, Guohui
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (18)
  • [3] Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer A Real-World Cost-Effectiveness Analysis
    Cromwell, Ian
    van der Hoek, Kimberly
    Melosky, Barbara
    Peacock, Stuart
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (12) : 2097 - 2103
  • [4] COST-EFFECTIVENESS OF NIVOLUMAB VS. DOCETAXEL AS SECOND-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER
    Shah, S.
    Matthews, S. E.
    Sarasani, S.
    Noel, S.
    Blanchette, C. M.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A732 - A732
  • [5] COST-EFFECTIVENESS IN THE SECOND-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE US
    Graham, C.
    Knox, H.
    Hess, L. M.
    Jen, M.
    Carter, Cuyun G.
    Chandrawansa, K.
    Boye, M.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A457 - A458
  • [6] Pemetrexed vs docetaxel cost analysis in second-line non-small cell lung cancer treatment
    Ravasio, Roberto
    [J]. FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2005, 6 (02) : 119 - 126
  • [7] Docetaxel and carboplatin as the second-line treatment of non-small cell lung cancer
    Pesek, M
    Holá, V
    [J]. LUNG CANCER: CURRENT TOPICS, 2001, : 155 - 160
  • [8] Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France
    Marine, Sivignon
    Stephane, Roze
    Nicolas, Plommet
    Felizzi, Federico
    Paracha, Noman
    Benjamin, Mazaleyrat
    Perol, Maurice
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (05) : 464 - 473
  • [9] A Cost-Effectiveness Analysis of Docetaxel versus Pemetrexed in Second-Line Chemotherapy for Stage IIIb or IV Non-Small Cell Lung Cancer in China
    Yu, Yong-feng
    Chen, Zhi-wei
    Zhou, Zhen
    Song, Zheng-bo
    Li, Zi-ming
    Jian, Hong
    Zhang, Yi-fei
    Lu, Shun
    [J]. CHEMOTHERAPY, 2010, 56 (06) : 472 - 477
  • [10] Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population
    Yumi Asukai
    Amparo Valladares
    Carlos Camps
    Eifiona Wood
    Kaisa Taipale
    Jorge Arellano
    Alejo Cassinello
    José Antonio Sacristán
    Tatiana Dilla
    [J]. BMC Cancer, 10
12345